BIOGEN INC. Notes Payable, Fair Value Disclosure
BIOGEN INC. (BIIB) had Notes Payable, Fair Value Disclosure of $5.57 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:NotesPayableFairValueDisclosure · last filed 2026-04-29
- 2026-03-31: Notes Payable, Fair Value Disclosure $5.57B.
- 2025-12-31: Notes Payable, Fair Value Disclosure $5.68B.
- 2025-09-30: Notes Payable, Fair Value Disclosure $5.66B.
- 2025-06-30: Notes Payable, Fair Value Disclosure $5.55B.
| Period end | Notes Payable, Fair Value Disclosure |
|---|---|
| 2026-03-31 | $5.57B 10-Q · filed 2026-04-29 |
| 2025-12-31 | $5.68B 10-Q · filed 2026-04-29 |
| 2025-09-30 | $5.66B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $5.55B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $5.47B 10-Q · filed 2025-05-01 |
| 2024-12-31 | $5.44B 10-Q · filed 2025-10-30 |
| 2024-09-30 | $5.68B 10-Q · filed 2024-10-30 |
| 2024-06-30 | $5.45B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $5.78B 10-Q · filed 2024-04-24 |
| 2023-12-31 | $6.29B 10-Q · filed 2024-10-30 |
| 2020-12-31 | $8.52B 10-K · filed 2021-02-03 |
| 2019-12-31 | $6.55B 10-K · filed 2021-02-03 |
| 2018-12-31 | $6.04B 10-K · filed 2020-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |